ArticleJournal of virology2006
Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.
Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 87 citations in OpenAlex.
- Human Metapneumovirus (HMPV): Advances in Diagnosis, Molecular Epidemiology, and Clinical Impact of an Underrecognized Respiratory Virus.Diagnostics (Basel, Switzerland) · 2026Review
- Immunological insights into the re-emergence of human metapneumovirus.Current opinion in immunology · 2025Review
- Clinical human metapneumovirus isolates show distinct pathogenesis and inflammatory profiles but similar CD8mSphere · 2024Article
- Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus.Human vaccines & immunotherapeutics · 2023Article
- A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.Frontiers in microbiology · 2022Article
- Novel HLA-B7-restricted human metapneumovirus epitopes enhance viral clearance in mice and are recognized by human CD8Scientific reports · 2021Article
- The role of M2-2 PDZ-binding motifs in pulmonary innate immune responses to human metapneumovirus.Journal of medical virology · 2020Article
- Human Metapneumovirus Escapes NK Cell Recognition through the Downregulation of Stress-Induced Ligands for NKG2D.Viruses · 2020Article
- Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Prophylactic and therapeutic approaches for human metapneumovirus.Virusdisease · 2018Review
- The CD8 T Cell Response to Respiratory Virus Infections.Frontiers in immunology · 2018Review
- Human metapneumovirus - what we know now.F1000Research · 2018Review
- Detection of Nuclear Protein Profile Changes by Human Metapneumovirus M2-2 Protein Using Quantitative Differential Proteomics.Vaccines · 2017Article
- Functional motifs responsible for human metapneumovirus M2-2-mediated innate immune evasion.Virology · 2016Article
- Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.PLoS pathogens · 2016Article
- Modulation of Host Immunity by the Human Metapneumovirus.Clinical microbiology reviews · 2016Review
- Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.Vaccine · 2016Article
- Immune Response to Human Metapneumovirus Infection: What We Have Learned from the Mouse Model.Pathogens (Basel, Switzerland) · 2015Review
- Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.Journal of virology · 2015Article
- New Approaches for Immunization and Therapy against Human Metapneumovirus.Clinical and vaccine immunology : CVI · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (hMPV) has emerged as an important human respiratory pathogen causing upper and lower respiratory tract infections in young children and older adults. In addition, hMPV infection is associated with asthma exacerbation in young children. Recent epidemiological evidence indicates that hMPV may cocirculate with human respiratory syncytial virus (hRSV) and mediate clinical disease similar to that seen with hRSV. Therefore, a vaccine for hMPV is highly desirable. In the present study, we used predictive bioinformatics, peptide immunization, and functional T-cell assays to define hMPV cytotoxic T-lymphocyte (CTL) epitopes recognized by mouse T cells restricted through several major histocompatibility complex class I alleles, including HLA-A*0201. We demonstrate that peptide immunization with hMPV CTL epitopes reduces viral load and immunopathology in the lungs of hMPV-challenged mice and enhances the expression of Th1-type cytokines (gamma interferon and interleukin-12 [IL-12]) in lungs and regional lymph nodes. In addition, we show that levels of Th2-type cytokines (IL-10 and IL-4) are significantly lower in hMPV CTL epitope-vaccinated mice challenged with hMPV. These results demonstrate for the first time the efficacy of an hMPV CTL epitope vaccine in the control of hMPV infection in a murine model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.